Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Cantalupo A, Di Lorenzo A. S1P Signaling and De Novo Biosynthesis in Blood Pressure Homeostasis. J Pharmacol Exp Ther. 2016;358(2):359-70.

Testo N, Olson LC, Subramaniyam S, Hanson T, Magro CM. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. Am J Dermatopathol. 2016;38(10):769-74.

Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. Clin Nephrol. 2016;85(3):184-8.

Salvatore SP, Myers-Gurevitch PM, Chu S, Robinson BD, Dadhania D, Seshan SV. Polyoma (BK) virus associated urothelial carcinoma originating within a renal allograft five years following resolution of polyoma virus nephropathy. Clin Nephrol. 2016;85(3):179-83.

2015

D'Alfonso TM, Moo T-, Arleo EK, Cheng E, Antonio LB, Hoda SA. Cystic Neutrophilic Granulomatous Mastitis: Further Characterization of a Distinctive Histopathologic Entity Not Always Demonstrably Attributable to Corynebacterium Infection. Am J Surg Pathol. 2015;39(10):1440-7.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, M Y Wang V, et al. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov. 2015;5(6):636-51.

Priolo C, Loda M. Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. Mol Cell Oncol. 2015;2(4):e1001197.

Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, Strauss RG, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126(18):2153-61.

Yigit N, Wu WW, Subramaniyam S, Mathew S, Geyer JT. BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. Cancer Genet. 2015;208(7-8):404-7.

Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015;94(11):1875-83.